MedTrace Logo

Camrelizumab Combined With Apatinib for Recurrent Resistant GTN

NCT04047017 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2021-07-30

No results posted yet for this study

Summary

This study is to evaluate the efficacy and safety of camrelizumab plus apatinib in patients with high-risk chemo-refractory or relapsed GTN.

Conditions

  • Gestational Trophoblastic Disease

Interventions

DRUG

Apatinib

250mg, po, qd

DRUG

Camrelizumab

200mg, q2w

Sponsors & Collaborators

  • Peking Union Medical College Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-08
Primary Completion
2021-03-18
Completion
2021-05-15

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04047017 on ClinicalTrials.gov